Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.

Tinker AV, Hirte HW, Provencher D, Butler M, Ritter H, Tu D, Azim HA Jr, Paralejas P, Grenier N, Hahn SA, Ramsahai J, Seymour L.

Clin Cancer Res. 2019 Oct 15;25(20):6052-6060. doi: 10.1158/1078-0432.CCR-19-0298. Epub 2019 Jul 15.

PMID:
31308062
2.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL.

Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.

3.

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.

Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.

4.

Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model.

Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY, Butcher M, Bramson JL, Lee DA, Hirte HW, Ashkar AA.

Cancer Immunol Res. 2018 Oct;6(10):1174-1185. doi: 10.1158/2326-6066.CIR-18-0144. Epub 2018 Jul 17.

5.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.

Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM.

JAMA Oncol. 2018 Jul 12;4(7):e173776. doi: 10.1001/jamaoncol.2017.3776. Epub 2018 Jul 12.

6.

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.

Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, Wang L, Liu G, Zhou C, Blattler C, Ivy SP, Oza AM.

Gynecol Oncol. 2015 May;137(2):216-22. doi: 10.1016/j.ygyno.2015.03.005. Epub 2015 Mar 11.

PMID:
25769658
7.

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Chu QS, Sangha R, Hotte SJ, Sergenson G, Schnell D, Chand VK, Hirte HW.

Invest New Drugs. 2014 Dec;32(6):1226-35. doi: 10.1007/s10637-014-0139-9. Epub 2014 Jul 19.

PMID:
25037863
8.

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).

Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ.

Br J Cancer. 2013 Aug 20;109(4):943-9. doi: 10.1038/bjc.2013.380. Epub 2013 Jul 18.

9.

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma.

Hirte HW.

Onco Targets Ther. 2013 Apr 18;6:427-35. doi: 10.2147/OTT.S30373. Print 2013.

10.

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E.

Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4. Epub 2013 May 5.

11.

Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.

Tran B, Brown AM, Bedard PL, Winquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, Ghai S, Shaw P, Petrocelli T, Hudson TJ, Neel BG, Onetto N, Siu LL, McPherson JD, Kamel-Reid S, Dancey JE.

Int J Cancer. 2013 Apr 1;132(7):1547-55. doi: 10.1002/ijc.27817. Epub 2012 Oct 11.

12.

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.

Razak AR, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, Walsh W, Stayner LA, Laughlin A, Novotny-Diermayr V, Zhu J, Eisenhauer EA.

Br J Cancer. 2011 Mar 1;104(5):756-62. doi: 10.1038/bjc.2011.13. Epub 2011 Feb 1.

13.

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL.

Clin Cancer Res. 2011 Mar 15;17(6):1582-90. doi: 10.1158/1078-0432.CCR-10-1893. Epub 2011 Jan 28.

14.

Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.

Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, Macalpine K, Wright JJ, Oza AM.

Int J Gynecol Cancer. 2010 Jul;20(5):787-93. doi: 10.1111/IGC.0b013e3181e273a8.

PMID:
20847613
15.

Novel developments in angiogenesis cancer therapy.

Hirte HW.

Curr Oncol. 2009 May;16(3):50-4.

16.

Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.

Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, Spanik S, Wagnerova M, Hirte HW, Kaye S, Johri AR, Oza AM.

J Clin Oncol. 2009 Jul 1;27(19):3097-103. doi: 10.1200/JCO.2008.20.4826. Epub 2009 May 18.

PMID:
19451434
17.

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL.

Clin Cancer Res. 2009 May 20;27(15S). pii: 3528.

18.

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM.

Clin Cancer Res. 2008 Jun 1;14(11):3450-5. doi: 10.1158/1078-0432.CCR-07-1416.

19.

Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.

Hirte HW, Hotte SJ.

J Clin Oncol. 2008 Jul 10;26(20):3301-2. doi: 10.1200/JCO.2008.16.3972. Epub 2008 May 19. No abstract available.

PMID:
18490647
20.

Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents.

Pond GR, Siu LL, Moore M, Oza A, Hirte HW, Winquist E, Goss G, Hudes G, Townsley CA.

J Clin Oncol. 2008 Mar 10;26(8):1324-30. doi: 10.1200/JCO.2007.14.0673.

PMID:
18323557
21.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

22.

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review.

Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM.

Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1194-204. Epub 2007 Jun 1. Review.

PMID:
17540006
23.

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.

Welch S, Hirte HW, Carey MS, Hotte SJ, Tsao MS, Brown S, Pond GR, Dancey JE, Oza AM.

Gynecol Oncol. 2007 Aug;106(2):305-10. Epub 2007 May 29.

PMID:
17537491
24.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B.

Oncologist. 2007 Apr;12(4):426-37. Review.

25.

An optimized clinical regimen for the oncolytic virus PV701.

Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O'Neil JD, Roberts MS, Groene WS, Major PP.

Clin Cancer Res. 2007 Feb 1;13(3):977-85.

26.

Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.

Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM.

Cancer. 2007 Feb 15;109(4):692-702. Review.

27.

Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.

Townsley CA, Pond GR, Oza AM, Hirte HW, Winquist E, Goss G, Degendorfer P, Moore MJ, Siu LL.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2141-9.

28.

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW.

Ann Oncol. 2006 Feb;17(2):334-40. Epub 2005 Nov 10.

PMID:
16284058
29.

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B.

Ann Oncol. 2005 Oct;16(10):1688-94. Epub 2005 Jul 8.

PMID:
16006586
30.

A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L.

Invest New Drugs. 2005 Mar;23(2):165-70.

PMID:
15744593
31.

A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.

MacKenzie MJ, Hirte HW, Siu LL, Gelmon K, Ptaszynski M, Fisher B, Eisenhauer E.

Ann Oncol. 2004 Apr;15(4):665-70.

PMID:
15033677
32.

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

Daneshmand M, Parolin DA, Hirte HW, Major P, Goss G, Stewart D, Batist G, Miller WH Jr, Matthews S, Seymour L, Lorimer IA.

Clin Cancer Res. 2003 Jul;9(7):2457-64.

33.

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

Hotte SJ, Hirte HW.

Curr Pharm Des. 2002;8(25):2249-53. Review.

PMID:
12369852
34.

Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.

Richardson M, Gunawan J, Hatton MW, Seidlitz E, Hirte HW, Singh G.

Gynecol Oncol. 2002 Sep;86(3):279-87.

PMID:
12217749
35.

Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials.

Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B; Cancer Care Ontario Practice Guidelines Initiative Gynecology Disease Site Group.

Eur J Gynaecol Oncol. 2002;23(2):104-10. Review.

PMID:
12013102
36.

Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.

Duivenvoorden WC, Popović SV, Lhoták S, Seidlitz E, Hirte HW, Tozer RG, Singh G.

Cancer Res. 2002 Mar 15;62(6):1588-91.

37.
38.

Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure.

Jeyabalan N, Hirte HW, Moens F.

Int J Gynecol Cancer. 2000 Nov;10(6):463-468.

PMID:
11240716
39.

Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells.

Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, Piaggio G, Sacchi A, Pontecorvi A, Bacchetti S, Farsetti A.

Mol Cell Biol. 2000 Jun;20(11):3764-71.

40.
41.
42.

A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.

Hirte HW, Miller D, Tonkin K, Findlay B, Capstick V, Murphy J, Buckman R, Carmichael J, Levine M, Hill W.

Gynecol Oncol. 1997 Jan;64(1):80-7.

PMID:
8995552
43.

Telomerase activity associated with acquisition of malignancy in human colorectal cancer.

Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S.

Cancer Res. 1995 Jun 15;55(12):2533-6.

44.

Transient global amnesia associated with acute heparin-induced thrombocytopenia.

Warkentin TE, Hirte HW, Anderson DR, Wilson WE, O'Connell GJ, Lo RC.

Am J Med. 1994 Nov;97(5):489-91. No abstract available.

PMID:
7977439
45.

Establishment and characterization of four human epithelial ovarian carcinoma cell lines.

Hirte HW, Kaiser JS, Bacchetti S.

Cancer. 1994 Aug 1;74(3):900-6.

PMID:
8039117
46.

Telomerase activity in human ovarian carcinoma.

Counter CM, Hirte HW, Bacchetti S, Harley CB.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2900-4.

47.

Telomerase, cell immortality, and cancer.

Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S, Hirte HW, Counter CM, Greider CW, et al.

Cold Spring Harb Symp Quant Biol. 1994;59:307-15. Review. No abstract available.

PMID:
7587082
49.

A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma.

Hirte HW, Clark DA, Mazurka J, O'Connell G, Rusthoven J.

Gynecol Oncol. 1992 Mar;44(3):223-6.

PMID:
1531803
50.

Supplemental Content

Loading ...
Support Center